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Abstract: Aldehyde dehydrogenase 1 family member A2 (ALDH1A2) is a rate-limiting enzyme
involved in cellular retinoic acid synthesis. However, its functional role in ovarian cancer remains
elusive. Here, we found that ALDH1A2 was the most prominently downregulated gene among ALDH
family members in ovarian cancer cells, according to complementary DNA microarray data. Low
ALDH1A2 expression was associated with unfavorable prognosis and shorter disease-free and overall
survival for ovarian cancer patients. Notably, hypermethylation of ALDH1A2 was significantly
higher in ovarian cancer cell lines when compared to that in immortalized human ovarian surface
epithelial cell lines. ALDH1A2 expression was restored in various ovarian cancer cell lines after
treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Furthermore, silencing DNA
methyltransferase 1 (DNMT1) or 3B (DNMT3B) restored ALDH1A2 expression in ovarian cancer
cell lines. Functional studies revealed that forced ALDH1A2 expression significantly impaired the
proliferation of ovarian cancer cells and their invasive activity. To the best of our knowledge, this is
the first study to show that ALDH1A2 expression is regulated by the epigenetic regulation of DNMTs,
and subsequently that it might act as a tumor suppressor in ovarian cancer, further suggesting that
enhancing ALDH1A2-linked signaling might provide new opportunities for therapeutic intervention
in ovarian cancer.
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1. Introduction
Ovarian cancer has the highest mortality rate among all gynecological cancers because most cases
are not diagnosed until the disease has reached an advanced stage [1]. Although the five-year survival
rate for ovarian cancer patients has substantially improved, owing to ongoing efforts to develop an
effective screening strategy [1], the lack of reliable methods for early diagnosis and the absence of
specific symptoms result in diagnoses at advanced stages [1]. Furthermore, approximately 80% of
women with advanced ovarian cancer show tumor progression or, more commonly, recurrence [2].
Thus, understanding the pathogenesis of ovarian cancer and the molecular mechanism of its early
stage is crucial for the management of this lethal, highly metastatic disease.
The aldehyde dehydrogenase 1 (ALDH1) family comprises major enzymes that produce retinoic
acid (RA) via the oxidation of all-trans retinal and 9-cis-retinal, which is mainly involved in biological
functions related to cell differentiation, cell cycle arrest, and eventually, apoptosis [3–5]. The ALDH1A
Cancers 2019, 11, 1553; doi:10.3390/cancers11101553 www.mdpi.com/journal/cancers
Cancers 2019, 11, 1553 2 of 18
subfamily consists of three members, ALDH1A1, ALDH1A2, and ALDH1A3 [6]. ALDH1A1 participates
in retinal oxidation, acetaldehyde metabolism, and detoxification of cyclophosphamide, whereas the
ALDH1A2 and ALDH1A3 proteins are integral to the oxidation of retinal to RA [7]. Interestingly,
despite similarities in the structure and function of the isoenzymes of the ALDH1A subfamily [8],
several lines of evidence suggest that these molecules might perform different functions in cancer
progression [7–14]. ALDH1A1 has been implicated in conferring resistance to certain anticancer agents,
such as cyclophosphamide, and was shown to play a functional role in cancer stem cells [11,12]. In
contrast to that of ALDH1A1, low ALDH1A2 expression has been associated with an unfavorable
prognosis in prostate cancer and head and neck squamous cell carcinoma patients [13,14]. Meanwhile,
ALDH1A3 plays important roles in several metabolic and physiological processes [15], which potentially
suggest different roles for ALDH1A isoforms in cancer progression. However, the functions and
prognostic value of ALDH1A2 in ovarian cancer progression remain unclear.
The methylation of CpG sites is an epigenetic mechanism underlying the regulation of gene
expression, which usually leads to gene silencing [16]. Aberrant methylation of gene promoter regions
is one of the earliest molecular alterations that occurs during carcinogenesis and a key mechanism for
the inactivation of tumor suppressor genes [16–18]. Therefore, methylation has emerged as a promising
marker for the early detection of cancer [19]. In fact, CpG islands in tumor suppressor genes such as
CDKN2B, BRACA1, RASSF1A, MLH1, RARB2, and TIMP3 undergo aberrant methylation in ovarian
cancer [20]. DNA methylation patterns have been shown to be regulated by DNA methyltransferases
(DNMTs), including DNMT1, DNMT3A, and DNMT3B [21]. DNMT1 is essential for maintaining DNA
methylation patterns in proliferating cells [22], whereas DNMT3A and DNMT3B are required for de
novo methylation during embryonic development [23]. However, there are no reports regarding the
epigenetic regulation of ALDH1A2 by DNMTs in human ovarian cancer.
Therefore, in this study, we evaluated the expression profiles of ALDH isozyme-encoding genes
in ovarian cancer using a complementary DNA (cDNA) microarray. Additionally, we focused on the
role of ALDH1A2 as one of the most prominently downregulated genes in ovarian cancer.
2. Results
2.1. Reduced Expression of ALDH1A2 in Ovarian Cancer
To evaluate whether ALDH isozymes contribute to the progression of ovarian cancer, an Illumina
microarray was used to identify differentially expressed ALDH genes in six ovarian cancer cell lines
(YDOV-139, YDOV-157, YDOV-161, YDOV-13, YDOV-105, and YDOV-151) and four human ovarian
surface epithelial (HOSE) cell lines (HOSE 198, 209, 211, and 213) [24]. RNA isolated from the cells
was directly compared by hybridization with cDNA microarrays with 24,957 probe sets. The volcano
plot shows that 24,957 genes were differentially expressed (p < 0.01 and fold change > 2) in the cancer
cells compared to the normal cells (Figure 1A). We found that 15 ALDH isoforms exhibited differential
expression patterns in the ovarian cancer cell lines compared to the normal cells (Figure 1A,B, Table
S1). ALDH1A2, ALDH1B1, and ALDH9A1 were downregulated in the ovarian cancer cells compared
to the expression in HOSE cells (Figure 1A and Table S1), whereas ALDH3A1 was upregulated in
the ovarian cancer cells. Among these isoforms, we further characterized the functional role of
ALDH1A2 in ovarian cancer progression, because it was one of the most prominently downregulated
genes, with approximately 50-fold lower expression levels in ovarian cancer cells than in normal cells
(Figure 1B, Table S1). These decreased expression levels were further validated by real-time PCR,
and immunoblotting in ovarian cancer cell lines (SNU840, RMG1, OVCA433, OVCA429, and SKOV3)
and IHOSE8695 cells (Figure 1C,D). Taken together, these observations suggest that the expression of
ALDH1A2 is strongly downregulated in ovarian cancer.
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Figure 1. Comparative analysis of ALDH gene expression profiles and ALDH1A2 protein expression 
in ovarian  cancer  cell  lines.  (A) Volcano plot of  the distribution of differentially  expressed genes 
between  ovarian  cancer  cell  lines  (YDOV‐139, YDOV‐157, YDOV‐161, YDOV‐13, YDOV‐105,  and 
YDOV‐151) and human ovarian surface epithelial  (HOSE) cell  lines  (HOSE 198, 209, 211, and 213) 
using a DNA microarray. The volcano plot shows that 24,957 genes were differentially expressed (p < 
0.01 and fold change > 2). The −log10 (p‐value) of each gene is plotted against the log 2 ratio of cancer 
intensity  to  normal  intensity.  Vertical  dotted  lines  in  red  and  green  correspond  to  a  2.0‐fold 
upregulation and 2.0‐fold downregulation of expression, respectively. Horizontal black dotted lines 
indicate  the  significance  level  at  p  =  0.01.  Plots were  generated  using  ExDEGA  v.1.6.5  software 
(Ebiogen, Seoul, Republic of Korea). (B) Up‐ and downregulation of gene expression were examined 
in six ovarian cancer cell lines (YDOV‐139, YDOV‐157, YDOV‐161, YDOV‐13, YDOV‐105, and YDOV‐
151) and four HOSE cell  lines (HOSE 198, 209, 211, and 213) using a DNA microarray. The values 
indicate fold changes in the expression levels of each gene in the ovarian cancer cell lines relative to 
those  in  the HOSE  cell  lines. Data  are  expressed  as  the means   ±  SD.  Statistical  significance was 
assessed using an unpaired t‐test. * p < 0.001, ** p < 0.05. (C) Real‐time PCR of the cDNA microarray 
results of ALDH1A2 in ovarian cancer cell lines and immortalized HOSE cells. The 18S rRNA gene 
was used as the endogenous control to normalize the data. (D) Immunoblotting analysis of ALDH1A2 
expression in ovarian cancer cell lines and immortalized HOSE cells, with β‐actin used as a loading 
control. The changes in the protein levels were estimated by quantification of band intensities with 
the ImageJ software. The protein levels were normalized to the signal of ‐actin. 
2.2. ALDH1A2 Is Hypermethylated in Ovarian Cancer 
Methylation of CpG islands in gene promoter regions is known to be a mechanism underlying 
the inactivation of tumor suppressor genes, which is associated with the aberrant silencing of their 
transcription  [25]. Thus, we  first analyzed  the DNA methylation status of  the ALDH1A2 gene  in 
ovarian cancer cell lines, RMG1, SKOV3, and OVCA433, which express  low ALDH1A2 relative to 
levels  in  IHOSE8695,  using  conventional methylation‐specific  PCR  analysis  (MSP). Methylation‐
specific PCR analysis revealed that the methylation of ALDH1A2 was markedly higher in ovarian 
Figure 1. Comparative analysis of ALDH gene expression profiles and LD 1 2 protein expression in
ovarian cancer cell lines. (A) Volcano plot of the distribution of differentially expressed genes between
ovarian cancer cell lines (YDOV-139, YDOV-157, YDOV-161, YDOV-13, YDOV-105, and YDOV-151)
and human ovarian surface epithelial (HOSE) cell lines (HOSE 198, 209, 211, and 213) using a DNA
microarray. The volcano plot shows that 24,957 genes were differentially expressed (p < 0.01 and fold
change > 2). The −log10 (p-value) of each gene is plotted against the log 2 ratio of cancer intensity
to normal intensity. Vertical dotted lines in red and green correspond to a 2.0-fold upregulation
and 2.0-fold downregulation of expression, respectively. Horizontal black dotted lines indicate the
significance level at p = 0.01. Plots were generated using ExDEGA v.1.6.5 software (Ebiogen, Seoul,
Republic of Korea). (B) Up- and downregulation of gene expression were examined in six ovarian
cancer cell lines (YDOV-139, YDOV-157, YDOV-161, YDOV-13, YDOV-105, and YDOV-151) and four
HOSE cell lines (HOSE 198, 209, 211, and 213) using a DNA microarray. The values indicate fold
changes in the expression levels of each gene in the ovarian cancer cell lines relative to those in the
HOSE cell lines. Data are expressed as the means ± SD. Statistical significance was assessed using
an unpaired t-test. * p < 0.001, ** p < 0.05. (C) Real-time PCR of the cDNA microarray results of
ALDH1A2 in ovarian cancer cell lines and immortalized HOSE cells. The 18S rRNA gene was used as
the endogenous control to normalize the data. (D) Immunoblotting analysis of ALDH1A2 expression
in ovarian cancer cell lines and immortalized HOSE cells, with β-actin used as a loading control. The
changes in the protein levels were estimated by quantification of band intensities with the ImageJ
software. The protein levels were normalized to the signal of β-actin.
2.2. ALDH1A2 Is Hypermethylated in Ovarian Cancer
Methylation of CpG islands in gene promoter regions is known to be a mechanism underlying
the inactivation of tumor suppressor genes, which is associated with the aberrant silencing of their
transcription [25]. Thus, we first analyzed the DNA methylation status of the ALDH1A2 gene in
ovarian cancer cell lines, RMG1, SKOV3, and OVCA433, which express low ALDH1A2 relative to levels
in IHOSE8695, using conventional methylation-specific PCR analysis (MSP). Methylation-specific PCR
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analysis revealed that the methylation of ALDH1A2 was markedly higher in ovarian cancer cell lines
(RMG1, SKOV3, and OVCA433) than in IHOSE8695 cells (Figure 2A). qRT-PCR demonstrated that
the low levels of ALDH1A2 expression in ovarian cancer cell lines were reversed following treatment
with the demethylation agent 5-Aza-CdR (Figure 2B). Next, we further confirmed the methylation
status of the ALDH1A2 gene in a public dataset, Methylation and Expression database of Normal
and Tumor tissues (MENT), and found that ALDH1A2 was significantly hypermethylated in ovarian
cancer tissues compared to that in normal ovarian tissues (Figure 2C). In addition, correlation analysis
of methylation and gene expression levels revealed a negative correlation (Spearman’s r = −0.1462,
p < 0.0005) between DNA methylation and the gene expression of ALDH1A2 (Figure 2D). Taken
together, these data suggest that ALDH1A2 expression is downregulated via gene methylation in
ovarian cancer.
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ALDH1A2 mRNA levels in 5‐Aza‐CdR‐treated and control cells. GAPDH was used as loading control. 
(C) Methylation  status of ALDH1A2  in  the Methylation and Expression database of Normal and 
Tumor  tissues  (MENT;  http://mgrc.kribb.re.kr:8080/MENT/).  A Mann–Whitney  test was  used  to 
evaluate  statistical  significances.  ** p < 0.05.  (D) Correlation between DNA methylation and gene 
expression of ALDH1A2 were determined by Spearman’s correlation through the MENT database 
with clinical data with the TCGA ov dataset. 
2.3. DNMTs Are Negative Upstream Regulators of ALDH1A2 Expression 
Since the DNMT family plays a pivotal role in maintaining DNA methylation patterns [21], we 
monitored the expression of different DNMT genes in ovarian cancer patients through the publicly 
available database Oncomine. The mRNA levels of DNMT1, DNMT3A, and DNMT3B were strongly 
elevated  in  ovarian  cancer  tissues  compared  to  those  in  normal  ovarian  tissues,  according  to 
Oncomine  (Figure 3A). To determine whether  the silencing of DNMT  in ovarian cancer cells can 
rescue the DNA hypermethylation of ALDH1A2, RMG1 cells were transfected with siRNA specific 
Figure 2. ethylation status of the ALDH1A2 gene in ovarian cancer. (A) Analysis of ALDH1A2
methylation in RMG1, SKOV3, and OVCA433 cells by methylation-specific PCR. U, primer pair
specific to unmethylated DNA; M, primer pair specific to methylated DNA. (B) qRT-PCR analysis
of ALDH1A2 mRNA levels in 5-Aza-CdR-treated and control cells. GAPDH was used as loading
control. (C) Methylation status of ALDH1A2 in the Methylation and Expression database of Normal
and Tumor tissues (MENT; http://mgrc.kribb.re.kr:8080/MENT/). A Mann–Whitney test was used to
evaluate statistical significances. ** p < 0.05. (D) Correlation between DNA methylation and gene
expression of ALDH1A2 were determined by Spearman’s correlation through the MENT database with
clinical data with the TCGA ov dataset.
2.3. DNMTs Are Negative Upstream Regulators of ALDH1A2 Expression
Since the DNMT family plays a pivotal role in maintaining DNA methylation patterns [21], we
monitored the expression of different DNMT genes in ovarian cancer patients through the publicly
available database Oncomine. The mRNA levels of DNMT1, DNMT3A, and DNMT3B were strongly
elevated in ovarian cancer tissues compared to those in normal ovarian tissues, according to Oncomine
(Figure 3A). To determine whether the silencing of DNMT in ovarian cancer cells can rescue the DNA
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hypermethylation of ALDH1A2, RMG1 cells were transfected with siRNA specific for the different
DNMT genes (DNMT1, DNMT3A, and DNMT3B). The silencing of different DNMT genes by siRNA
was confirmed by real-time PCR (Figure 3B). siRNA silencing of DNMT1 or DNMT3B restored the
expression of ALDH1A2 and reduced methylation in ovarian cancer cells, whereas no significant
changes in ALDH1A2 expression were observed upon knockdown of DNMT3A (Figure 3C,D). These
results demonstrated that DNMT1 and DNMT3B contribute to the hypermethylation of ALDH1A2,
suggesting that they negatively regulate ALDH1A2 expression in ovarian cancer.
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2.4. ALDH1A2 Overexpression Attenuates the Proliferation and Invasion Potential of Ovarian Cancer Cell 
Lines 
To elucidate the function of reduced ALDH1A2 in ovarian cancer progression, we constructed 
the pCMV‐TagB‐Flag‐ALDH1A2 expression vector to overexpress ALDH1A2 in ovarian cancer cell 
lines. The overexpression of this construct in RMG1, SKOV3, and OVCA433 cells was confirmed by 
immunoblot  analysis  using  antibodies  against  ALDH1A2  or  Flag  (Figure  4A)  and  by 
immunocytochemistry  with  anti‐Flag  antibodies  (Figure  S1).  Forced  expression  of  ALDH1A2 
Figure 3. DNA methyltransferase (DNMT) is an upstream regulator of ALDH1A2 expression. (A) Data
on the mRNA expression of DNMT1, DNMT3A, and DNMT3B obtained from the Oncomine database
(http://www.oncomine.com). A Mann–Whitney test was used to evaluate statistical significances.
* p < 0.001. (B) Expression of DNMT1, DNMT3A, and DNMT3B in RMG1 cells, as determined by
real-time PCR. Knockdown of DNMT1, DNMT3A, and DNMT3B was performed by transfecting
RMG1 cells with specific siRNAs, siDNMT1, siDNMT3A, and siDNMT3B, respectively. Nontargeting
siRNA (siCont) was used as a control. The 18S rRNA gene was used as the endogenous control to
normalize the data. Data are expressed as the means ± SD. Statistical significance was assessed using an
unpaired t-test. * p < 0.001. (C) Analysis of ALDH1A2 methylation by methylation-specific PCR after
knockdown of DNMT1, DNMT3A, and DNMT3B in RMG1 cells. Knockdown of DNMT1, DNMT3A,
and DNMT3B was performed by transfecting RMG1 cells with specific siRNAs, siDNMT1, siDNMT3A,
and siDNMT3B, respectively. The lysates were subjected to methylation-specific PCR. Nontargeting
siRNA (siCont) was used as a control. U, primer pair specific to unmethylated DNA; M, primer pair
specific to methylated DNA. (D) ALDH1A2 expression after transfection of RMG1 cells with siDNMT1,
siDNMT3A, or siDNMT3B, as determined by real-ti e PCR. Nontargeting siRNA (siCont) was used as
a control. The 18S rRNA gene was used as the endogenous control to normalize the real-time PCR data.
** p < 0.05, *** p < 0.005.
2.4. ALDH1A2 Overexpression Attenuates the Proliferation and Invasion Potential of Ovarian Cancer
Cell Lines
To elucidate the function of reduced ALDH1A2 in ovarian cancer progression, we constructed
the pCMV-TagB-Flag-ALDH1A2 expression vector to overexpress ALDH1A2 in ovarian cancer
cell lines. The overexpression of this construct in RMG1, SKOV3, and OVCA433 cells was
confirmed by immunoblot analysis using antibodies against ALDH1A2 or Flag (Figure 4A) and by
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immunocytochemistry with anti-Flag antibodies (Figure S1). Forced expression of ALDH1A2 decreased
cell proliferation in a time-dependent manner and induced S-phase cell cycle arrest (Figure 4B,C,
Figure S2A), whereas it failed to affect cell death (Figures S2B and S3). Furthermore, the forced
expression of ALDH1A2 significantly impaired the invasive behavior of RMG1 cells (Figure 5A,B).
We further confirmed the effect of ALDH1A2 overexpression on the invasive capacity of cells by
using Matrigel-embedded sprouting assays, which was evaluated as their ability to spread from
3D-matrigel spheroids (Figure 5C). The ALDH1A2 construct-transfected cells showed significantly
lower spreading capacity than the empty vector-transfected cells. Next, as ALDH1A2 is the first
enzyme to produce RA, we investigated the effect of ATRA, an active vitamin A metabolite, on inducing
the constitutive activation of retinoid signaling. Treatment of ovarian cancer cell lines with ATRA
significantly impaired their invasive capacity and spread from 3D Matrigel spheroids (Figure 5D).
Collectively, these observations suggested that ALDH1A2 plays a critical role in mediating the invasion
activity of ovarian cancer cells.
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Figure 4. Effects of forced expression of ALDH1A2 on the proliferation of vari n cancer cells. (A) Cells
wer transf cted with vector expressing Flag-tagged ALDH1A2 or empty vector. After 24 h, w ole
lysates were immunoblotted wi h anti-ALDH1A2 and ti-Flag antibodies. β-Actin was s as
a loading contr l. Densitometric analysi was performed J soft are. The protein l vels
wer normalized to the signal of β-acti . (B,C) Effects of forced expression of ALDH1A2 on the
proliferation of ovarian cancer cell lines. ll ere transfected with Flag-tagged ALDH1A2 or empty
vector. After indicated times, phase c trast i ages ere observed (B). The cells were trypsinized
with trypsin–EDTA, and the number of viable cells ( ) as determined by a Vi-Cell XR cell viability
analyzer at indicated time points. Original agnification: 20×. Statistical significance was assessed
using an unpaired t-test. ** p < 0.05.
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Figure 5. Effects of forced expression of ALDH1A2 on invasive potential of ovarian cancer cells.
(A,B) Invasion assay; RMG-I cells transfected with either the empty vector or ALDH1A2 expression
vector for 24 h were loaded into the upper chamber and then fetal bovine serum (FBS, 5%) was added
to the lower chamber. After 24 h, the cells that invaded the lower chamber were stained with DiffQuik
(A) and quantified (B) under a microscope. Data are expressed as eans ± SD. Statistical significance
was assessed using n unpaired t-test. *** p < 0.005. (C) Sprouting assay; RMG1 cells ectopically
expressing ALDH1A2 were embedded with Matrigel and incubated for 24 h. Phase contrast images
were observed (left panel). Calcein-AM-stained cells were visualized using a fluorescence microscope
(right panel). Original magnification: 4×. Scale bar, 500 µm. (D) Sprouting assay using RMG1 cells
incubated in the presence or absence of ATRA (1 µM, 5 µM). Phase contrast images were observed
(left panel). Calcein-AM-stained cells were visualized using a fluorescence microscope (right panel).
Original magnification: 4×. Scale bar, 500 µm.
2.5. Downregulation of ALDH1A2 Correlates with Poor Prognosis in Ovarian Cancer Patients
To elucidate the clinical significance of ALDH1A2 in ovarian cancer patients, we compared
ALDH1A2 expression levels by immunohistochemistry in benign, borderline, and malignant ovarian
tumor tissues and in normal ovarian/fallopian epithelial tissues (Figure 6A). ALDH1A2 expression
showed an obvious decrease with tumor progression from normal epithelium to ovarian cancer tissues
(Figure 6B). The expression levels of ALDH1A2 are summarized in Table 1 according to clinical
pathological characteristics of ovarian cancer patients. ALDH1A2 immunoreactivity was associated
with an early tumor stage (p < 0.001) and serous cell type (p < 0.001; Figure 6C).
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Poor  105  54.7  74.6 (58.6–90.6)  0–279   
CA125          0.598 
Negative  34  16.4  92.5 (58.3–126.6)  0–282   
Positive (>35 U/mL)  173  83.6  83.7 (70.7–96.7)  0–280   
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Figure 6. Reduced L 1 2 expression correlates ith poor prognosis in ovarian cancer patients.
(A) Representative i ages of i unohistoche ical staining of ALD 1A2 expression in epithelial
ovarian tissues fro benign, borderline, and carcino a patients and in nonadjacent nor al tissues
(Scale bar: 250 µm). (B,C) Box plot depicting the immunohistochemical staining data. Histoscores were
computed based on the intensity and tissue area of positive staining. * p < 0.001.
Table 1. Expression of ALDH1A2 in relation to clinicopathological characteristics of ovarian cancer patients.
Characteristics No. % Mean Score (95% CI) Range p-Value
All study subjects 446 100 136.4 (127.7–145.1) 0–287
Diagnostic category <0.001
Normal 71 15.9 240.8 (232.7–248.9) 109–286
Benign 109 24.4 174.0 (164.2–183.8) 57–287
Borderline 56 12.6 127.1 (103.9–150.4) 5–271
Cancer 210 47.1 84.2 (72.1–96.1) 0–282
FIGO stage <0.001
I–II 59 28.1 126.4 (99.6–153.1) 0–282
III–IV 131 61.9 75.5 (61.8–89.2) 0–273
Recurrent 20 10.0 18.9 (11.2–26.6) 0–66
Cell type <0.001
Serous 144 68.6 67.9 (54.9–81.0) 0–279
Others 66 31.4 119.4 (95.7–143.2) 0–282
Tumor grade 0.142
Well/Moderate 87 45.3 93.2 (73.6–112.8) 0–282
Poor 105 54.7 74.6 (58.6–90.6) 0–279
CA125 0.598
Negative 34 16.4 92.5 (58.3–126.6) 0–282
Positive (>35 U/mL) 173 83.6 83.7 (70.7–96.7) 0–280
Platinum sensitivity 0.984
Sensitive 174 90.6 81.8 (68.8–94.8) 0–280
Resistant 18 9.4 82.2 (34.0–130.5) 6–270
FIGO, International Federation of Gynecology and Obstetrics; CA125, cancer antigen 125; CI, confidence interval.
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We next examined the relationship between ALDH1A2 protein expression and patient survival
outcomes. The Kaplan–Meier plots demonstrated that the patients with lower ALDH1A2 expression,
as well as patients with advanced tumor stage (stage III/IV), displayed shorter disease-free (p < 0.001)
and overall (p < 0.001) survival (Figure 7A–D). Multivariate analysis showed that ALDH1A2 expression
(p = 0.012), FIGO stage (p < 0.001), and tumor grade (p = 0.032) were independent prognostic factors for
disease-free survival (Table 2). The Cox proportional hazards model also showed that high ALDH1A2
expression (hazard ratio = 0.42, 95% confidence interval (CI) = 0.20–0.85, p = 0.016), high tumor stage
(hazard ratio = 3.06, 95% CI = 1.18–7.93, p = 0.021), serous cell type (hazard ratio = 2.63, 95% CI =
1.03–6.73, p = 0.042), and old age (hazard ratio = 1.94, 95% CI = 1.06–3.53, p = 0.030) were independent
prognostic factors of overall survival. Thus, these results show that ALDH1A2 expression is correlated
with tumorigenesis, patient survival rate, and disease recurrence rate in ovarian cancer.
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Figure 7. Kaplan–Meier survival curve for patients with epithelial ovarian cancer. (A,B) Patients
with ALDH1A2− tumors (histoscore < 70) showed significantly worse disease-free (A) and overall
survival (B) than patients with ALDH1A2+ tumors. (C,D) Patients with advanced stages (III/IV)
showed significantly worse disease-free (C) and overall survival (D) than patients with early-stage
ovarian cancer.
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Table 2. Univariate and multivariate analysis of the associations between prognostic variables and disease-free and overall survival in epithelial ovarian cancer patients.
Variable Disease-Free Survival Hazard Ratio (95% CI), p-Value Overall Survival Hazard Ratio (95% CI), p-Value
Univariate Multivariate Univariate Multivariate
FIGO stage (III–IV) 6.40 (3.31–12.34), <0.001 3.81 (1.84–7.86), <0.001 5.09 (2.02–12.86), 0.001 3.06 (1.18–7.93), 0.021
Cell type (serous) 3.03 (1.80–5.11), <0.001 1.69 (0.92–3.09), 0.087 4.52 (1.79–11.38), 0.001 2.63 (1.03–6.73), 0.042
Tumor grade (poor) 1.95 (1.28–2.96), 0.002 1.60 (1.04–2.46), 0.032 1.68 (0.94–3.00), 0.076 NA
CA125+ (>35 U/mL) 2.38 (1.20–4.73), 0.013 1.05 (0.49–2.27), 0.882 2.21 (0.79–6.16), 0.127 NA
Age (>50 years) 1.57 (1.06–2.34), 0.024 1.28 (0.84–1.95), 0.247 2.12 (1.17–3.84), 0.013 1.94 (1.06–3.53) 0.030
ALDH1A2+ 0.37 (0.24–0.58), <0.001 0.54 (0.33–0.87), 0.012 0.30 (0.15–0.60), 0.001 0.42 (0.20–0.85), 0.016
FIGO, International Federation of Gynecology and Obstetrics; CA125, cancer antigen 125; CI, confidence interval; NA, not applicable.
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3. Discussion
In the present study, we identified ALDH1A2 as one of the most prominently downregulated
ALDH genes in ovarian cancer cells, as compared to the expression in normal cells, based on microarray
analysis. In addition, lower ALDH1A2 expression was correlated with poor prognosis in ovarian
cancer patients. Furthermore, the ALDH1A2 gene was found to be hypermethylated via DNMT1 or
DNMT3B in ovarian cancer cell lines, indicating that ALDH1A2 expression is regulated by epigenetic
regulation via DNMT. The overexpression of ALDH1A2 also suppressed the proliferation and invasive
ability of ovarian cancer cells. Taken together, our results suggest that ALDH1A2 might act as a tumor
suppressor gene in ovarian cancer.
Indeed, compelling evidence has emerged in recent years, supporting a tumor-suppressive role
of ALDH1A2. The expression of ALDH1A2 was shown to be reduced in cancer tissues compared to
that in normal epithelial regions, which was associated with an unfavorable prognosis in prostate
and head and neck cancers [13,14]. Furthermore, high ALDH1A2 transcription levels correlated with
improved overall survival in breast cancer patients [26]. Seidensaal et al. [14] reported that inhibition
of ALDH1A2 induces the loss of cell adhesion and a mesenchymal-like phenotype by regulating Twist,
vimentin, and N-cadherin, thus indicating the possibility that low ALDH1A2 expression could be
associated with an unfavorable prognosis. However, it had not been determined whether reduced
ALDH1A2 is relevant to the early diagnosis of ovarian cancer. In these studies, we found that low
ALDH1A2 expression gradually decreased with tumor progression from a normal epithelium to
ovarian cancer tissues. The expression of ALDH1A2 at an advanced stage (stage III/IV) is lower than
that at an early tumor stage (stage I/II). Furthermore, in stage I ovarian cancer (n = 44), CA125 was
elevated in 28 (63.6%) of 44 patients. Of the 16 patients who presented false negative results for CA125,
eight (50.0%) were ALDH1A2-negative (data not shown). Thus, these observations support our notion
that ALDH1A2 is a potential biomarker contributing to early cancer detection, in conjunction with
CA125, and prediction of prognosis. Therefore, these data led us to speculate that ALDH1A2 might be
a tumor inhibitor in ovarian cancer.
Aberrant DNA methylation is widely considered one of the earliest molecular changes leading
to the inactivation of tumor suppressor genes in carcinogenesis [16–21]. In ovarian cancer, aberrant
methylation of CpG islands in tumor suppressor genes, including CDKN2B, BRCA1, APC, RASSF1,
and CDH13, is a frequent event compared to that in the normal ovarian surface epithelium [27,28]. Tam
et al. [29] observed that the frequency of methylation was the highest in ovarian cancer, followed by that
in borderline and benign tissues, thus indicating that the detection of alterations in DNA methylation
patterns has the potential to be applied for the detection of early-stage or, possibly, premalignant disease.
Notably, methylation of circulating tumor DNA (ctDNA), which is tumor-derived fragmented DNA in
the bloodstream, has been observed in ovarian cancer [30]. Methylation of genes such as RARB2, APC,
CDKN2A, and RUNX3 has been shown to decrease following surgery in breast, esophageal, liver, and
gastric cancers [31]. This suggests the possibility that monitoring the methylation of tumor-specific
genes in blood could offer an alternative approach for tracking tumor response to therapy. However, to
our knowledge, there has been no report regarding the epigenetic regulation of ALDH1A2 in human
ovarian cancer. Here, we showed that a low level of ALDH1A2 expression in ovarian cancer was
correlated with hypermethylation of the gene. Treatment of ovarian cancer cells with the demethylating
agent 5-Aza-CdR reversed the repression of ALDH1A2 expression. Importantly, the hypermethylation
of ALDH1A2 genes seems to be a common feature in various cancers such as brain tumors and prostate,
colon, and kidney cancers, according to the MENT database (Figure S1). This suggests that ALDH1A2
is a novel hypermethylated gene in cancer. However, the detailed mechanism underlying the link
between ALDH1A2 methylation and ovarian cancer progression requires further investigation. In the
present study, although mRNA expression of ALDH1A2 in OVCA3 cells was low compared with that in
normal cells, we failed to detect low levels of ALDH1A2 protein in OVCA3 cells. These results suggest
the possibility that ALDH1A2 expression in OVCA3 cells may be regulated by post-transcriptional
modifications of mRNA or action of miRNA. Due to the fact that the biological function of ALDH1A2 is
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exerted by the protein and not by the RNA, and OVCA3 cells display normal ALDH1A2 protein levels,
this cell line represents an exception to the widespread ALDH1A2 downregulation in ovarian cancer.
DNMT are a conserved family of cytosine methylases with a key role in epigenetic regulation [32].
High expression of DNMT3A or DNMT3B has been observed in a large number of specimens from
cancer patients, and increased DNMT3A expression is implicated in hepatocellular carcinogenesis [33].
Exosomal DNMT1 enhances the resistance to cisplatin in ovarian cancer cells [34]. Leu et al. [35]
suggested that the downregulation of DNMT1 protein restores the expression of some inactive genes,
such as RASSF1A and HIN-1, through a decrease in their methylation levels in an ovarian cancer
cell line. Consistent with the data of these reports, we observed that the mRNA levels of DNMT1,
DNMT3A, and DNMT3B were elevated in ovarian cancer tissues compared to those in normal epithelial
ovarian cells. However, only the loss of DNMT1 or DNMT3B significantly restored the ALDH1A2
expression in ovarian cancer cell lines. These observations further support our notion that expression
of ALDH1A2 is regulated by epigenetic regulation in ovarian cancer.
Although we observed the epigenetic regulation of ALDH1A2, the underlying mechanism of
the correlation between low ALDH1A2 expression and aggressive disease in ovarian cancer remains
unclear. A possible mechanism for the tumor suppressive effect of methylated ALDH1A2 can be
mediated through RA signaling. Most biological effects of RA are mediated through retinoic acid
receptors (RARα, RARβ, RARγ). RA treatment is known to induce the expression of RARβ, which
functions as a tumor suppressor gene [36]. We observed that RARβ mRNA expression was low
in ovarian cancer cell lines, relative to that in normal cells with our cDNA microarrays (Figure S5).
Furthermore, we found that RARRES1, retinoic acid receptor responder 1, was strongly downregulated
(approximately 14-fold) in ovarian cancer cells lines (Figure S5). The impaired mRNA levels of RARβ
and RARRES1 in ovarian cancer tissues were further confirmed in the Oncomine database, suggesting
that expression of retinoid-related genes is altered in human ovarian cancer cells (Figure S6). A recent
study suggested that inhibition of ALDH1A2-RAR signaling induces loss of cell adhesion and gain of
a mesenchymal-like phenotype [14]. Therefore, the methylation-silenced expression of ALDH1A2 may
be responsible for lower RA levels and altered RA-linked signaling, contributing to the development
of ovarian cancer progression. Another possible mechanism is via the PI3K/AKT/mTOR pathway,
which is known as a potential predictor of the distinct invasive and migratory capacities of human
ovarian cancer cells [37], but we failed to detect phosphorylation of AKT by ALDH1A2 overexpression
in ovarian cancer cells (data not shown).
In summary, we obtained novel evidence showing that low expression levels of ALDH1A2 are
correlated with an early tumor stage and poor prognosis for ovarian cancer patients, and that its
expression is negatively regulated by the methylation of ALDH1A2 via DNMT1 or DNMT3B. Therefore,
we suggest that DNA methylation of ALDH1A2 and the expression of ALDH1A2 might serve as
reliable markers for the early diagnosis of disease to improve the outcome for patients with ovarian
cancer, considering that an accurate and timely diagnosis is often crucial for treatment selection. These
findings further raise the possibility that the methylation of ALDH1A2 could help to distinguish
between relatively indolent and aggressive tumors, which can aid in decision making between more
aggressive or less aggressive treatment and monitoring.
4. Materials and Methods
4.1. Cell Culture and Reagents
Human ovarian cancer cell lines, SKOV3, OVCA3, OVCA433, and OVCA429 were obtained from
the American Type Culture Collection (Manassas, VA, USA). SNU-840 cells were purchased from
Korea Cell Line Bank (KCLB, Seoul, Korea). RMG-I cells were purchased from Japanese Collection
of Research Bioresources Cell Bank (JCRB, Tokyo, Japan). All purchased cell lines were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS;
HyClone, UT, USA) and 1% antibiotics (Cellgro, Manassas, VA, USA). Six ovarian cancer cell lines
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(YDOV-139, YDOV-157, YDOV-161, YDOV-13, YDOV-105, and YDOV-151) and four HOSE cell lines
(HOSE 198, 209, 211, and 213), which had been previously established [24], were maintained in a 1:1
mixture of Medium 199 and MCDB 105 (Sigma, St. Louis, MO, USA) supplemented with 10% FBS
(Gemini Bio-Products, Calabasas, CA, USA). Immortalized HOSE8695 (IHOSE8695) cells had been
established previously [38] and were maintained in DMEM supplemented with 10% FBS (HyClone,
UT, USA) and 1% antibiotics (Cellgro, Manassas, VA, USA). All cell lines were incubated at 37 ◦C
in a humidified incubator with 5% CO2. All-trans retinoic acid (ATRA) and 5-aza-2′-deoxycytidine
(5-Aza-CdR) were purchased from Sigma (St. Louis, MO, USA).
4.2. Western Blot Analysis
For Western blot analysis, cells were harvested and lysed with ice-cold RIPA buffer (25 mM
tris–HCl, pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% sodium dodecyl sulfate)
containing a protease inhibitor cocktail (Roche Applied Science, Mannheim, Germany). Proteins from
cell lysates were resolved by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then
transferred to a nitrocellulose membrane (Pierce, Rockford, IL, USA) using an electric transfer system.
The membrane was incubated with the following antibodies: anti-ALDH1A2, anti-Flag (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), and anti-β-actin (Sigma–Aldrich) as a loading control. The
membrane was then incubated with horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit
secondary antibodies, and immunoreactive bands were visualized using enhanced chemiluminescence
reagents (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
4.3. RNA Preparation and cDNA Microarray Hybridization
Total RNA was extracted and purified from six ovarian cancer cell lines (YDOV-139, YDOV-157,
YDOV-161, YDOV-13, YDOV-105, and YDOV-151) and four human ovarian surface epithelial (HOSE)
cell lines (HOSE 198, 209, 211, and 213) using the TRIzol reagent (Invitrogen Life Technologies, Carlsbad,
CA, USA) and the RNeasy kit (Qiagen, Inc., Valencia, CA, USA) according to the manufacturers’
suggested protocols. Probes were prepared for each cell line and hybridized independently in
the microarrays. Thus, the array comprised of 10 samples—6 tumor and 4 normal—that were
appropriately grouped for differential expression analysis. Biotinylated cRNA was produced by T7
in vitro transcription using the Ambion Illumina RNA amplification kit (Ambion, Inc., Austin, TX,
USA). We verified the quality of total RNA by gel analysis with the total RNA Nano chip assay on
an Agilent 2100 bioanalyzer (Agilent Technologies GmbH, Berlin, Germany). We performed chip
hybridization, washing, cyanine 3–streptavidin (GE Healthcare, Amersham Biosciences, Uppsala,
Sweden) staining, and scanning on the Illumina Bead Station 500 platform (Illumina, Inc., San Diego,
CA, USA) using reagents and protocols supplied by the manufacturer. Hybridization of 750 ng of
labeled cRNA was performed with biological duplicates on a Sentrix Human Ref-6-V2 Expression Bead
chip (Illumina, San Diego, CA, USA) Scanning of arrays was performed using an Illumina Bead Array
reader confocal scanner (Illumina, San Diego, CA, USA) according to the manufacturer’s instructions.
Our records have been assigned the following GEO accession number: GSE135508.
4.4. Quantitative Reverse Transcription–Polymerase Chain Reaction (qRT-PCR) and Real-Time PCR
Total RNA was extracted from cells using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and
1.25 µg of the total RNA was used for cDNA synthesis with the Maxima first-strand cDNA synthesis kit
(Thermo Fisher Scientific, Villebon-sur-Yvette, France) according to the manufacturer’s protocol. PCR
products were amplified with the primers listed in Table S1. qRT-PCR was performed and the data
were analyzed on a C1000 thermal cycler (Bio-Rad, Hercules, CA, USA) using the following program:
33 cycles of denaturation at 95 ◦C for 30 s, annealing at 58 ◦C (ALDH1A2) or 58 ◦C (glyceraldehyde
3-phosphate dehydrogenase, GAPDH) for 30 s, and elongation at 72 ◦C for 40 s. The PCR products
were evaluated by 1.8% agarose gel electrophoresis, using the GAPDH gene transcript as a control,
and visualized using a Gel Doc XR molecular imager system (Bio-Rad, Hercules, CA, USA).
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Real-time PCR was performed using the TOPreal™ qPCR 2× premix (SYBR Green with high ROX;
Enzynomics) on an Applied Biosystems 7300 real-time PCR system (Applied Biosystems, Darmstadt,
Germany). The reaction conditions were as follows: preincubation at 94 ◦C for 10 min, followed by
40 cycles of 94 ◦C for 10 s, 60 ◦C for 15 s, and 72 ◦C for 15 s, and a melting curve program, with the
temperature rising from 60 ◦C to 95 ◦C. Relative mRNA expression levels were calculated using the
comparative cycle threshold (2−∆∆Ct) method, with the 18S rRNA gene used as the endogenous control
to normalize the data.
4.5. Methylation-Specific PCR Analysis
Genomic DNA was isolated from cultured cells with the GeneJET Genomic DNA Purification Kit
(Thermo Fisher Scientific Baltics UAB, and Vilnius, Lithuania). Bisulfite modification of genomic DNAs
was performed using the EpiJET Bisulfite Conversion Kit (Thermo Fisher Scientific Baltics UAB, and
Vilnius, Lithuania) according to the manufacturer’s protocol. ALDH1A2 is associated with a ~1.5 kb
CpG island at its 5′ end, overlapping with the transcription start site [13]. For methylation-specific PCR
analysis, we amplified a 200 bp region within the CpG island upstream of the ALDH1A2 transcription
start site using primer pairs specific for either methylated or unmethylated bisulfite-modified sequences
(Table S2), as previously reported [13]. PCR was performed on a C1000 thermal cycler instrument
(Bio-Rad, Hercules, CA, USA) using 200 ng of a bisulfite-modified DNA template, 1× EpiTaq PCR
buffer, 0.3 mM dNTPs, 2.5 mM MgCl2, 200 ng of each primer, and 1.25 U EpiTaq DNA polymerase
(TaKaRa EpiTaq™ HS for bisulfite-treated DNA; Takara, Nagoya, Japan) in a 50 µL reaction for 40
cycles (94 ◦C, 30 s; 65 ◦C, 45 s; and 72 ◦C, 1 min), followed by a 1.8% agarose gel electrophoresis and
visualization using a Gel Doc XR molecular imager system (Bio-Rad, Hercules, CA, USA).
4.6. Public Databases
DNA methylation analysis of the ALDH1A2 gene in normal and ovarian tumor tissues of
ovarian cancer patients was performed using the Methylation and Expression database of Normal
and Tumor tissues (MENT; http://mgrc.kribb.re.kr:8080/MENT/), together with clinical data from the
Gene Expression Omnibus (GEO) database (GEO accession numbers: GSE26989, GSE28648, GSE31826,
and ov) and The Cancer Genome Atlas (TCGA, ov dataset). Methylation values were calculated
as the average beta value for measuring methylation levels at each CpG site, ranging from 0 (least
methylated) to 1 (most methylated). No further normalization of the derived beta value was performed.
We selected cg00930873A for CpG probes from the MENT database for the beta values. Despite the
large number of cancer samples, the difference in the group size was too large to be a meaningful
statistic for the beta value in ovarian cancer. Relative to cancer samples, the normal sample size was
too small. Therefore, data manipulations for patient selection were considered. A percentile cutoff
for the beta value was selected at the 95th percentile, and genes were sorted by their beta value at
the selected cutoff. Sorting data are displayed as a box plot. Statistical analyses were performed
with the one-tailed Mann-Whitney test using GraphPad Prism 7 because the data did not follow a
normal distribution. Correlation analysis of DNA methylation and the gene expression of ALDH1A2
was performed using MENT with clinical data from the TCGA ov dataset. mRNA levels of DNMT1,
DNMT3A, and DNMT3B in ovarian cancer patients were determined by analysis of the TCGA Ki
dataset, which is available through Oncomine (Compendia Bioscience, https://www.oncomine.org).
4.7. ALDH1A2 Expression Constructs and Transfection
The full-length coding sequence of ALDH1A2 was PCR-amplified from a cDNA of IHOSE8695
using gene-specific primers, AAGCCCGGGCGGATCCATGACTTCCAGCAAGATA (forward) and
GCTTGATATCGAATTCTTAGGAGTTCTTCTGGGG (reverse). The sequence was cloned in-frame
into the BamHI and EcoRI sites of pCMV-Tag2B-Flag (Stratagene, La Jolla, CA, USA) and confirmed by
DNA sequencing. Subsequently, cells were plated and transfected with pCMV-Tag2B-Flag-ALDH1A2
or the empty vector using the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s
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recommendations. Whole cell lysates were subjected to Western blotting analysis for the confirmation
of ALDH1A2 expression.
4.8. Cell Proliferation Assay
Cells were plated at a density of 0.2 × 106 cells per well in 6-well plates and cultured for 24 h. The
cells were then transfected with the ALDH1A2 expression vector or empty vector for 24 h and incubated
for the indicated times at 37 ◦C. After the incubation, the cells were trypsinized with trypsin–EDTA,
and the number of viable cells was determined by a Vi-Cell XR cell viability analyzer (Beckman Coulter,
Inc., Brea, CA, USA).
4.9. Invasion Assay
To monitor the invasive potential of ovarian cancer cells, an invasion assay was performed using a
10-well Chemotaxis Chamber (Neuro Probe, Inc., Gaithersburg, MD, USA) with a 8 µm polycarbonate
filter (Neuro Probe, Inc., Gaithersburg, MD, USA) coated with rat tail collagen type I (BD Bioscience)
according to the manufacturer’s instructions. Briefly, 2 × 104 cells were resuspended in a serum-free
medium (285 µL) and plated onto the upper chamber. As a chemoattractant, DMEM containing 5%
FBS (400 µL) was added to the lower chamber, and the chamber was incubated at 37 ◦C in a humidified
incubator with 5% CO2. After 24 h, the membranes were fixed with 100% methanol and stained with a
DiffQuik stain kit (Triangle Biomedical Sciences, Inc., Durham, NC, USA). The uninvaded cells were
removed from the upper surface of the membrane, and the invaded cells were counted in six random
high-power fields per filter using an Axio Imager M2 microscope (Carl Zeiss, Thornwood, NY, USA).
Each experiment was repeated three times.
4.10. Matrigel-Embedded Sprouting Assay
The sprouting assay was performed according to a previously described method [39]. Briefly,
cells were spotted at a density of 1×106 cells and embedded in a 1:1 mixture of DMEM and growth
factor-reduced Matrigel in a 6-well plate. After polymerization at 37 ◦C, the cells were incubated with
DMEM supplemented with 10% FBS for 24h. Then, cells were stained with calcein-AM (Invitrogen,
Carlsbad, CA, USA) to visualize cells that spread from the spheroid. Randomly chosen fields (4×) in
each well were photographed using a fluorescence microscope (EVOS FL; AMG).
4.11. Small Interfering RNA (siRNA) Transfection
siRNAs against DNMT1, DNMT3A, and DNMT3B and a negative control siRNA were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Cells were seeded at 2 × 105 cells per well
in 6-well plates and transfected with siRNAs (10 nM) using the Lipofectamine RNAiMAX reagent
(Invitrogen) according to the manufacturer’s instructions.
4.12. Tissue Specimens
A total of 210 ovarian cancer, 56 borderline, 109 benign, and 71 nonadjacent normal epithelial
tissues were obtained from patients at the Gangnam Severance Hospital between 1996 and 2010. Some
of the paraffin blocks were provided by the Korea Gynecologic Cancer Bank through the Bio and
Medical Technology Development Program of the Ministry of the National Research Foundation (NRF),
funded by the Korean government (MSIT) (NRF-2017M3A9B8069610). Tissue samples were collected
from patients after they provided written informed consent, and the study was approved by the
Regional Institutional Review Board of the Gangnam Severance Hospital (3-2018-0194). Ovarian cancer
was staged according to the International Federation of Gynecology and Obstetrics (FIGO) classification
and graded according to the World Health Organization grading system. Clinical and pathological
records were reviewed to collect data including age, surgical procedure, survival time, survival status,
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tumor grade, and cell type. The response to therapy was assessed according to the Response Evaluation
Criteria in Solid Tumors (RECIST; version 1.0) by spiral computed tomography [40].
4.13. Tissue Microarray Construction and Immunohistochemistry
Tissue microarrays were produced from archival formalin-fixed, paraffin-embedded tissue blocks,
and representative areas were meticulously selected from hematoxylin and eosin-stained slides. Tissue
cylinders of 1.0 mm in diameter were extracted from selected areas of donor blocks and transplanted
into recipient blocks using a tissue arrayer (Beecher Instruments, Inc., Silver Spring, MD, USA). For
immunohistochemical staining, the tissue microarray blocks were cut into serial 5 mm thick sections,
which were deparaffinized in xylene and rehydrated through a graded alcohol series to distilled water.
Heat-induced antigen retrieval was performed for 20 min in an antigen retrieval buffer, pH 6 (Dako,
Carpinteria, CA, USA). Endogenous peroxidase activity was blocked by incubation with 3% H2O2 for
10 min. The sections were incubated with an anti-ALDH1A2 mouse monoclonal antibody (clone no.
G-2; Santa Cruz Biotechnology) at a 1:200 dilution for 1 h. The antigen–antibody reaction was detected
with EnVision+ Dual Link System-HRP (Dako) and visualized with 3,3′-diaminobenzidine (Dako).
The stained sections were lightly counterstained with hematoxylin. Appropriate negative and positive
controls were concurrently analyzed.
Immunohistochemically stained slides were scanned by a NanoZoomer 2.0 HT (Hamamatsu
Photonics K.K., Hamamatsu City, Japan) with a 20× objective magnification (0.5 µm resolution). The
captured digital images were analyzed using the Visiopharm software version 4.5.1.324 (Visiopharm,
Hørsholm, Denmark). The intensity of brown staining (0 = negative, 1 = weak, 2 = moderate,
and 3 = strong) was obtained using a predefined algorithm and optimized settings. The overall
immunohistochemical score was calculated by multiplying the intensity and percentage of staining,
resulting in a score of 0 to 300. The Mann–Whitney U-test or Kruskal–Wallis test was used to
compare the protein expression levels between groups. For survival analysis, expression values were
dichotomized (positive vs. negative), with cutoff values showing the most discriminative power
(histoscore of 70 for ALDH1A2). Survival distributions were estimated using the Kaplan–Meier method
with a log-rank test. A Cox multivariate proportional hazards model was used to identify independent
predictors of survival. Statistical analysis was performed using SPSS version 23.0 (SPSS, Chicago, IL,
USA). In all cases, p < 0.05 was considered statistically significant.
4.14. Statistical Analysis
Results are expressed as the mean ± SD. based on the control. Statistical analyses were performed
with Student’s t-test, Mann–Whitney test, or Spearman’s rank correlation coefficient using GraphPad
Prism 7 (GraphPad Software, Inc., La Jolla, CA, USA). A p-value < 0.05 was considered as significant.
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